Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2012 - 2026)

Agios Pharmaceuticals' Change in Accured Expenses history runs 15 years deep, the most recent figure standing at -$19.2 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 26.57% year-over-year to -$19.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 173.69% YoY) and the FY2025 annual result came in at -$790000.0, down 186.23% from the prior year.
• Change in Accured Expenses was -$19.2 million for Q1 2026 at Agios Pharmaceuticals, down from $8.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $14.5 million in Q2 2025 and bottomed at -$26.1 million in Q1 2025.
• A 5-year average of -$1.1 million and a median of $1.4 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 1244.17% — and 2024, when it plunged 364.03%.
• Agios Pharmaceuticals' Change in Accured Expenses stood at $5.2 million in 2022, then sank by 143.4% to -$2.3 million in 2023, then surged by 523.51% to $9.6 million in 2024, then declined by 7.62% to $8.9 million in 2025, then sank by 316.47% to -$19.2 million in 2026.
• Business Quant data shows AGIO's Change in Accured Expenses at -$19.2 million in Q1 2026, $8.9 million in Q4 2025, and $1.9 million in Q3 2025.